World J Clin Med Case Rep | Volume 1, Issue 1 | Research Article | Open Access
Coniglione F1,2,3, Luciani F2,3*, Rocca FD2,3, Leggeri A4, Polici P5, Dibra A1 and Gargari M2,3
1Department of Surgical Science, Catholic University “Our Lady of Good Counsel”, Albania
2Department of Surgical Science, University of Roma “Tor Vergata”, Italy
3Department of Medical Science and Translation Medicine, U.O. Oral-Maxillofacial Surgery, University of Roma “Tor Vergata”, Italy
4University of Roma “Tor Vergata”, Italy
5Department of Medical Science, Catholic University “Our Lady of Good Counsel”, Albania
*Correspondance to: Fabio Luciani
Fulltext PDFThe fatty acid amide Palmitoylethanolamide (PEA) has been studied extensively for its anti- inflammatory and neuroprotective actions. The lipidic nature and large particle size of PEA in the native state may limit its solubility and bioavailability when given orally, however. Micronized formulations of a drug enhance its rate of dissolution and reduce variability of absorption when orally administered. The present study was thus designed to evaluate the oral anti-inflammatory efficacy of ultra-micronized-PEA. All cases were performed in Department of Oral-Maxillofacial Surgery of the University of Rome “Tor Vergata". A randomized, multicenter, single-blind, split-mouth trial, was carried out on 70 patients in whom 160 dental implants were placed. Participants were selected between September 2020 and October 2022. Patients showed symmetrical and bilateral edentulism’s in the posterior region of the jaw. Each of 70 patients was scheduled to undergo implants placement bilaterally; two surgical sessions were performed, the second sessions three months later from the first ones. Pharmacological protocol applied for each side of the same patient was based on ultra-micronized PEA 600 mg for sub-lingual use; in the test group patients assumed um-PEA 600 mg for sub-lingual use two times a day for a period of 30 days postoperatively. From the clinical research carried out by us, the preliminary results are very encouraging um-PEA was able to reduce significantly postoperative swelling and trismus. Additionally, this research showed that efficacy of um-PEA in decreasing pain and trismus after oral surgical procedures and this treatment did not show any serious side effect. Although the results we obtained were particularly encouraging, larger studies are needed to support the use of um-PEA in implant therapy and to evaluate its possible influence on the reduction of complications. In our opinion um-PEA administered sublingually, is useful in improving the postoperative comfort of the patient undergoing implant surgery.
UM-PEA; Dentistry; Implant surgery
Coniglione F, Luciani F, Rocca FD, Leggeri A, Polici P, Dibra A, et al. Efficacy of Ultra-Micronized Palmitoylethanolamide 600 MG (UM-PEA) for Sub-Lingual Use on Postoperative Course after Dental Implant Surgery: Multicentric Randomized Trial. World J Clin Med Case Rep. 2023; 1(1): 1006..